Abstract: The present invention relates to a pharmaceutical composition comprising monomeric alpha-lactalbumin complex, preferably LAC, which is an active complex of alpha-lactalbumin and a fatty acid or lipid with selective cytotoxic activity. The composition of the invention comprises insignificant amounts of oligomeric/multimeric alpha-lactalbumin complex, preferably LAC. Based on the selective cytotoxicity of the alpha-lactalbumin complex, preferably LAC composition such compositions are suitable for use in the manufacture of medicaments for use in therapy. Medicaments, comprising monomeric LAC are for use in the treatment of bacterial and viral infections and in particular cancer due to the selective cytotoxic activity. The application further relates to methods of producing a composition comprising monomeric alpha-lactalbumin complex, preferably LAC with cytotoxic activity.

Abstract: The invention relates to a process for preparing a high molecular weight lectin composition, in particular comprising the mannose-binding lectin (MBL). In one aspect there is provided a method for producing a composition comprising a variety of lectin molecules, wherein substantially all of said lectin molecules have a high molecular weight (above the molecular weight for dimer lectins). A precipitating agent is added to a lectin preparation comprising lectin molecules having a high molecular weight and lectin molecules having a low molecular weight (below or equal to the molecular weight for dimer lectins), and a precipitate and a supernatant are allowed to form. By separating said precipitate from said supernatant, a precipitate fraction comprising the high molecular weight lectin molecules is obtained.

Abstract: The present invention relates to a fusion protein capable of activating the complement system, the fusion protein comprising a first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof; and a second polypeptide sequence derived from a collectin or a functional homologue thereof; wherein said complement activating protein is not a collectin. A preferred fusion protein comprises amino acids of the L-ficolin sequence of FIG. 1 and amino acids of the MBL sequence shown in FIG. 2. The fusion protein is suitable for use in treatment consisting of creation, reconstitution, enhancing and/or stimulating the opsonic and/or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defence to recognise and kill microbial pathogens, and accordingly, the invention relates to a medicament comprising the fusion protein, methods for producing said fusion protein and methods for treating diseases, in particular infections.

Abstract: The invention relates to a process for isolating a lectin composition, in particular comprising the mannose-binding lectin (MBL), suitable for using recombinantly produced lectins as starting material, as well as methods for enriching a lectin preparation with respect to high molecular weight lectins. The method implies the use of sugar derivative modified solid supports, wherein the concentration of sugar derivatives on the solid support contributes to the isolation of predetermined oligomers of lectins.

Abstract: The present invention pertains to the use of subunits and oligomers of collectins and/or ficolins, such as mannan-binding lectin (MBL) in prophylactic and/or curative treatment of Severe Acute Respiratory Syndrome (SARS) in an individual.

Abstract: The invention relates to a process for preparing a high molecular weight lectin composition, in particular comprising the mannose-binding lectin (MBL), suitable for using recombinantly produced lectins as starting material, a high molecular weight lectin composition, a pharmaceutical composition comprising same, as well as the use of the produced composition for the preparation of a pharmaceutical composition for treating various conditions and diseases.

Abstract: The invention relates to a process for isolating a lectin composition, in particular comprising the mannose-binding lectin (MBL), suitable for using recombinantly produced lectins as starting material, as well as methods for enriching a lectin preparation with respect to high molecular weight lectins. The method implies the use of sugar derivative modified solid supports, wherein the concentration of sugar derivatives on the solid support contributes to the isolation of predetermined oligomers of lectins.

Abstract: The present invention relates to a method of shock heat treatment of polypeptides, to a stable polypeptide in a fluid medium, to a pharmaceutical composition comprising a stable polypeptide, to use of shock heat treatment for stabilizing a polypeptide, and to an industrial or large scale method of manufacturing a polypeptide comprising applying shock heat treatment during the manufacturing of the polypeptide.

Abstract: The present invention relates to a method of shock heat treatment of polypeptides, to a stable polypeptide in a fluid medium, to a pharmaceutical composition comprising a stable polypeptide, to use of shock heat treatment for stabilizing a polypeptide, and to an industrial or large scale method of manufacturing a polypeptide comprising applying shock heat treatment during the manufacturing of said polypeptide.